Are you over 18 and want to see adult content?
More Annotations
A complete backup of www.bbc.com/news/newsbeat-51563795
Are you over 18 and want to see adult content?
A complete backup of www.tv2.no/a/11221033/
Are you over 18 and want to see adult content?
A complete backup of punemirror.indiatimes.com/pune/others/maharashtra-board-hsc-exam-2020-state-board-ensures-measures-to-reduc
Are you over 18 and want to see adult content?
A complete backup of www.tvp.info/46721016/agent-tomek-zostal-zatrzymany
Are you over 18 and want to see adult content?
A complete backup of punemirror.indiatimes.com/pune/others/maharashtra-board-hsc-exam-2020-state-board-ensures-measures-to-reduc
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of trevisoeventi.com
Are you over 18 and want to see adult content?
A complete backup of pussyfreeloser.tumblr.com
Are you over 18 and want to see adult content?
A complete backup of torrentsjogos.com
Are you over 18 and want to see adult content?
A complete backup of drjonicewebb.com
Are you over 18 and want to see adult content?
A complete backup of nourishtheplanet.com
Are you over 18 and want to see adult content?
A complete backup of barpokeropen.com
Are you over 18 and want to see adult content?
Text
and in some
NEW PRODUCTS PAGE
Products. EXPAREL® (bupivacaine liposome injectable suspension) is a local analgesic administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain. *. The ioverao system is a handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targetedIOVERA | PACIRA
ioveraº allows health care providers to control pain by delivering precise, controlled doses of cold temperature to a targeted nerve The ioveraº technology represents a revolutionary cryotherapy platform The ioveraº system is a novel, FDA-approved non-opioid treatment that alleviates pain through a mechanism known as cryoanalgesia, which applies intensely focused cold therapy to a specificCONTACT PACIRA
Contact Us CONTACT PACIRA. × Science Center Campus. 10410 Science Center Drive San Diego, CA 92121 (858) 625 2424PRODUCTS | PACIRA
EXPAREL® (bupivacaine liposome injectable suspension) is changing the way we treat postsurgical pain Low- or no-opioid pain control is possible with EXPAREL EXPAREL is a local anesthetic administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain.CAREERS | PACIRA
Pacira BioSciences, Inc. is an Equal Opportunity Employer.All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, or protected veteran status and will INVESTORS | PACIRA BIOSCIENCES, INC. Pacira BioSciences at the 2021 Jefferies Virtual Healthcare Conference. Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of new pharmaceutical products, based on its proprietary DepoFoam® drug delivery technology, for use in hospitals and ambulatory surgerycenters.
INNOVATION DASHBOARD Pacira Innovation Hub The Innovation Hub features on-demand education covering a broad spectrum of topics designed to stimulate conversation and spark novel thinking in health care. Use the filters below to find the materials you are looking for or explore our Pacira Podcasts.DEPOFOAM | PACIRA
DepoFoam offers flexible delivery and can be designed to offer an immediate-release dose followed by sustained delivery. The ready-to-use aqueous solution works with narrow gauge needles and pen systems. DepoFoam membrane components are natural, well-tolerated, and cleared by normal metabolic pathways. DepoFoam permits systemicdelivery of
PACIRA BIOSCIENCES ANNOUNCES INVESTMENT IN SPINE BIOPHARMA -- Supports clinical advancement of lead candidate, Remedisc, for degenerative disc disease --PARSIPPANY, N.J., April 20, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced a $3 million investment in Spine BioPharma in the form of a convertible note. HOME | PACIRAABOUT USCOMMITMENTPRODUCTSPARTNERSHIPSNEWSEVENTS Learn More. Our iovera ° system is an FDA-approved handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targeted nerves, interrupting the nerve’s ability to transmit a pain signal. Results can be felt immediately after iovera ° treatment with pain relief that can last three months,and in some
NEW PRODUCTS PAGE
Products. EXPAREL® (bupivacaine liposome injectable suspension) is a local analgesic administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain. *. The ioverao system is a handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targetedIOVERA | PACIRA
ioveraº allows health care providers to control pain by delivering precise, controlled doses of cold temperature to a targeted nerve The ioveraº technology represents a revolutionary cryotherapy platform The ioveraº system is a novel, FDA-approved non-opioid treatment that alleviates pain through a mechanism known as cryoanalgesia, which applies intensely focused cold therapy to a specificCONTACT PACIRA
Contact Us CONTACT PACIRA. × Science Center Campus. 10410 Science Center Drive San Diego, CA 92121 (858) 625 2424PRODUCTS | PACIRA
EXPAREL® (bupivacaine liposome injectable suspension) is changing the way we treat postsurgical pain Low- or no-opioid pain control is possible with EXPAREL EXPAREL is a local anesthetic administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain.CAREERS | PACIRA
Pacira BioSciences, Inc. is an Equal Opportunity Employer.All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, or protected veteran status and will INVESTORS | PACIRA BIOSCIENCES, INC. Pacira BioSciences at the 2021 Jefferies Virtual Healthcare Conference. Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of new pharmaceutical products, based on its proprietary DepoFoam® drug delivery technology, for use in hospitals and ambulatory surgerycenters.
INNOVATION DASHBOARD Pacira Innovation Hub The Innovation Hub features on-demand education covering a broad spectrum of topics designed to stimulate conversation and spark novel thinking in health care. Use the filters below to find the materials you are looking for or explore our Pacira Podcasts.DEPOFOAM | PACIRA
DepoFoam offers flexible delivery and can be designed to offer an immediate-release dose followed by sustained delivery. The ready-to-use aqueous solution works with narrow gauge needles and pen systems. DepoFoam membrane components are natural, well-tolerated, and cleared by normal metabolic pathways. DepoFoam permits systemicdelivery of
PACIRA BIOSCIENCES ANNOUNCES INVESTMENT IN SPINE BIOPHARMA -- Supports clinical advancement of lead candidate, Remedisc, for degenerative disc disease --PARSIPPANY, N.J., April 20, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced a $3 million investment in Spine BioPharma in the form of a convertible note.ABOUT US | PACIRA
Pacira is the leading provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving patient outcomes We’re working to meet the needs of health care practitioners and their patients Our in-depth knowledge of non-opioid pain management, coupled with our passion for delivering improved patient care, drives our commitment to providing solutionsCONTACT PACIRA
Contact Us CONTACT PACIRA. × Science Center Campus. 10410 Science Center Drive San Diego, CA 92121 (858) 625 2424 INNOVATION DASHBOARD Pacira Innovation Hub The Innovation Hub features on-demand education covering a broad spectrum of topics designed to stimulate conversation and spark novel thinking in health care. Use the filters below to find the materials you are looking for or explore our Pacira Podcasts.MEDICAL MISSION
Introduction to Pacira. Pacira BioSciences, Inc. is committed to improving patient care through support of medical missions and charitable contributions aimed at underserved populations in low and middle income communities. Pacira supports recognized, independent, not-for-profit organizations, foundations, patient advocacyorganizations
PACIRA IN THE NEWS
Pacira BioSciences Reports Preliminary Net Product Sales of $44.6 Million for April 2021. 05/11/21. Pacira BioSciences Announces Notice of Allowance of New Patent for EXPAREL. 05/18/21. Pacira BioSciences to Present at the 2021 RBC Capital Markets Global Healthcare Conference. 05/12/21. Pacira BioSciences Reports Preliminary NetProduct Sales
PACIRA BIOSCIENCES REPORTS PRELIMINARY NET PRODUCT SALES April 2021 EXPAREL average daily sales were 449% of April 2020. PARSIPPANY, N.J., May 11, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited net product sales of EXPAREL ® (bupivacaine liposome injectable suspension) and iovera° of $43.1 PACIRA REPORTS RECORD REVENUE FOR 2020 OF $429.6 MILLION -- EXPAREL average daily sales at 109% of the prior year for the fourth quarter and 111% of the prior year for the month of December --PARSIPPANY, N.J., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the leading provider of innovative non-opioid pain management options, today reported preliminary unaudited net revenue of $429.6 million for 2020, a 2.0% increaseBOARD OF DIRECTORS
In June 2013, Mr. Stack was appointed as the Chairman of our board of directors. Mr. Stack was Managing Director of MPM Capital, a private equity firm, from 2005 through March 2017 and has been a Managing Partner of Stack Pharmaceuticals, Inc., a commercialization, marketing, and strategy firm, since 1998. From 2001 to 2004, he wasPresident
PACIRA BIOSCIENCES LAUNCHES NATIONAL REGIONAL ANESTHESIA The initiative aims to educate clinicians on ultrasound-guided regional approaches to manage postsurgical pain. PARSIPPANY, N.J., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), a leading provider of innovative non-opioid pain management options, today announced a collaboration with Envision Physician Services to train anesthesiology clinicians on PACIRA ANNOUNCES PUBLICATION OF PHASE 4 STUDY OF EXPAREL The Investor Relations website contains information about Pacira BioSciences, Inc.'s business for stockholders, potential investors, and financial analysts. HOME | PACIRAABOUT USCOMMITMENTPRODUCTSPARTNERSHIPSNEWSEVENTS Learn More. Our iovera ° system is an FDA-approved handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targeted nerves, interrupting the nerve’s ability to transmit a pain signal. Results can be felt immediately after iovera ° treatment with pain relief that can last three months,and in some
NEW PRODUCTS PAGE
Products. EXPAREL® (bupivacaine liposome injectable suspension) is a local analgesic administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain. *. The ioverao system is a handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targetedIOVERA | PACIRA
ioveraº allows health care providers to control pain by delivering precise, controlled doses of cold temperature to a targeted nerve The ioveraº technology represents a revolutionary cryotherapy platform The ioveraº system is a novel, FDA-approved non-opioid treatment that alleviates pain through a mechanism known as cryoanalgesia, which applies intensely focused cold therapy to a specificCONTACT PACIRA
Contact Us CONTACT PACIRA. × Science Center Campus. 10410 Science Center Drive San Diego, CA 92121 (858) 625 2424PRODUCTS | PACIRA
EXPAREL® (bupivacaine liposome injectable suspension) is changing the way we treat postsurgical pain Low- or no-opioid pain control is possible with EXPAREL EXPAREL is a local anesthetic administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain.CAREERS | PACIRA
Pacira BioSciences, Inc. is an Equal Opportunity Employer.All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, or protected veteran status and will INVESTORS | PACIRA BIOSCIENCES, INC. Pacira BioSciences at the 2021 Jefferies Virtual Healthcare Conference. Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of new pharmaceutical products, based on its proprietary DepoFoam® drug delivery technology, for use in hospitals and ambulatory surgerycenters.
INNOVATION DASHBOARD Pacira Innovation Hub The Innovation Hub features on-demand education covering a broad spectrum of topics designed to stimulate conversation and spark novel thinking in health care. Use the filters below to find the materials you are looking for or explore our Pacira Podcasts.DEPOFOAM | PACIRA
DepoFoam offers flexible delivery and can be designed to offer an immediate-release dose followed by sustained delivery. The ready-to-use aqueous solution works with narrow gauge needles and pen systems. DepoFoam membrane components are natural, well-tolerated, and cleared by normal metabolic pathways. DepoFoam permits systemicdelivery of
PACIRA BIOSCIENCES ANNOUNCES INVESTMENT IN SPINE BIOPHARMA -- Supports clinical advancement of lead candidate, Remedisc, for degenerative disc disease --PARSIPPANY, N.J., April 20, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced a $3 million investment in Spine BioPharma in the form of a convertible note. HOME | PACIRAABOUT USCOMMITMENTPRODUCTSPARTNERSHIPSNEWSEVENTS Learn More. Our iovera ° system is an FDA-approved handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targeted nerves, interrupting the nerve’s ability to transmit a pain signal. Results can be felt immediately after iovera ° treatment with pain relief that can last three months,and in some
NEW PRODUCTS PAGE
Products. EXPAREL® (bupivacaine liposome injectable suspension) is a local analgesic administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain. *. The ioverao system is a handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targetedIOVERA | PACIRA
ioveraº allows health care providers to control pain by delivering precise, controlled doses of cold temperature to a targeted nerve The ioveraº technology represents a revolutionary cryotherapy platform The ioveraº system is a novel, FDA-approved non-opioid treatment that alleviates pain through a mechanism known as cryoanalgesia, which applies intensely focused cold therapy to a specificCONTACT PACIRA
Contact Us CONTACT PACIRA. × Science Center Campus. 10410 Science Center Drive San Diego, CA 92121 (858) 625 2424PRODUCTS | PACIRA
EXPAREL® (bupivacaine liposome injectable suspension) is changing the way we treat postsurgical pain Low- or no-opioid pain control is possible with EXPAREL EXPAREL is a local anesthetic administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain.CAREERS | PACIRA
Pacira BioSciences, Inc. is an Equal Opportunity Employer.All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, or protected veteran status and will INVESTORS | PACIRA BIOSCIENCES, INC. Pacira BioSciences at the 2021 Jefferies Virtual Healthcare Conference. Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of new pharmaceutical products, based on its proprietary DepoFoam® drug delivery technology, for use in hospitals and ambulatory surgerycenters.
INNOVATION DASHBOARD Pacira Innovation Hub The Innovation Hub features on-demand education covering a broad spectrum of topics designed to stimulate conversation and spark novel thinking in health care. Use the filters below to find the materials you are looking for or explore our Pacira Podcasts.DEPOFOAM | PACIRA
DepoFoam offers flexible delivery and can be designed to offer an immediate-release dose followed by sustained delivery. The ready-to-use aqueous solution works with narrow gauge needles and pen systems. DepoFoam membrane components are natural, well-tolerated, and cleared by normal metabolic pathways. DepoFoam permits systemicdelivery of
PACIRA BIOSCIENCES ANNOUNCES INVESTMENT IN SPINE BIOPHARMA -- Supports clinical advancement of lead candidate, Remedisc, for degenerative disc disease --PARSIPPANY, N.J., April 20, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced a $3 million investment in Spine BioPharma in the form of a convertible note.ABOUT US | PACIRA
Pacira is the leading provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving patient outcomes We’re working to meet the needs of health care practitioners and their patients Our in-depth knowledge of non-opioid pain management, coupled with our passion for delivering improved patient care, drives our commitment to providing solutionsCONTACT PACIRA
Contact Us CONTACT PACIRA. × Science Center Campus. 10410 Science Center Drive San Diego, CA 92121 (858) 625 2424 INNOVATION DASHBOARD Pacira Innovation Hub The Innovation Hub features on-demand education covering a broad spectrum of topics designed to stimulate conversation and spark novel thinking in health care. Use the filters below to find the materials you are looking for or explore our Pacira Podcasts.MEDICAL MISSION
Introduction to Pacira. Pacira BioSciences, Inc. is committed to improving patient care through support of medical missions and charitable contributions aimed at underserved populations in low and middle income communities. Pacira supports recognized, independent, not-for-profit organizations, foundations, patient advocacyorganizations
PACIRA IN THE NEWS
Pacira BioSciences Reports Preliminary Net Product Sales of $44.6 Million for April 2021. 05/11/21. Pacira BioSciences Announces Notice of Allowance of New Patent for EXPAREL. 05/18/21. Pacira BioSciences to Present at the 2021 RBC Capital Markets Global Healthcare Conference. 05/12/21. Pacira BioSciences Reports Preliminary NetProduct Sales
PACIRA BIOSCIENCES REPORTS PRELIMINARY NET PRODUCT SALES April 2021 EXPAREL average daily sales were 449% of April 2020. PARSIPPANY, N.J., May 11, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited net product sales of EXPAREL ® (bupivacaine liposome injectable suspension) and iovera° of $43.1 PACIRA REPORTS RECORD REVENUE FOR 2020 OF $429.6 MILLION -- EXPAREL average daily sales at 109% of the prior year for the fourth quarter and 111% of the prior year for the month of December --PARSIPPANY, N.J., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the leading provider of innovative non-opioid pain management options, today reported preliminary unaudited net revenue of $429.6 million for 2020, a 2.0% increaseBOARD OF DIRECTORS
In June 2013, Mr. Stack was appointed as the Chairman of our board of directors. Mr. Stack was Managing Director of MPM Capital, a private equity firm, from 2005 through March 2017 and has been a Managing Partner of Stack Pharmaceuticals, Inc., a commercialization, marketing, and strategy firm, since 1998. From 2001 to 2004, he wasPresident
PACIRA BIOSCIENCES LAUNCHES NATIONAL REGIONAL ANESTHESIA The initiative aims to educate clinicians on ultrasound-guided regional approaches to manage postsurgical pain. PARSIPPANY, N.J., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), a leading provider of innovative non-opioid pain management options, today announced a collaboration with Envision Physician Services to train anesthesiology clinicians on PACIRA ANNOUNCES PUBLICATION OF PHASE 4 STUDY OF EXPAREL The Investor Relations website contains information about Pacira BioSciences, Inc.'s business for stockholders, potential investors, and financial analysts. HOME | PACIRAABOUT USCOMMITMENTPRODUCTSPARTNERSHIPSNEWSEVENTS Learn More. Our iovera ° system is an FDA-approved handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targeted nerves, interrupting the nerve’s ability to transmit a pain signal. Results can be felt immediately after iovera ° treatment with pain relief that can last three months,and in some
NEW PRODUCTS PAGE
Products. EXPAREL® (bupivacaine liposome injectable suspension) is a local analgesic administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain. *. The ioverao system is a handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targetedIOVERA | PACIRA
ioveraº allows health care providers to control pain by delivering precise, controlled doses of cold temperature to a targeted nerve The ioveraº technology represents a revolutionary cryotherapy platform The ioveraº system is a novel, FDA-approved non-opioid treatment that alleviates pain through a mechanism known as cryoanalgesia, which applies intensely focused cold therapy to a specificCONTACT PACIRA
Contact Us CONTACT PACIRA. × Science Center Campus. 10410 Science Center Drive San Diego, CA 92121 (858) 625 2424PRODUCTS | PACIRA
EXPAREL® (bupivacaine liposome injectable suspension) is changing the way we treat postsurgical pain Low- or no-opioid pain control is possible with EXPAREL EXPAREL is a local anesthetic administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain.CAREERS | PACIRA
Pacira BioSciences, Inc. is an Equal Opportunity Employer.All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, or protected veteran status and will INVESTORS | PACIRA BIOSCIENCES, INC. Pacira BioSciences at the 2021 Jefferies Virtual Healthcare Conference. Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of new pharmaceutical products, based on its proprietary DepoFoam® drug delivery technology, for use in hospitals and ambulatory surgerycenters.
INNOVATION DASHBOARD Pacira Innovation Hub The Innovation Hub features on-demand education covering a broad spectrum of topics designed to stimulate conversation and spark novel thinking in health care. Use the filters below to find the materials you are looking for or explore our Pacira Podcasts.DEPOFOAM | PACIRA
DepoFoam offers flexible delivery and can be designed to offer an immediate-release dose followed by sustained delivery. The ready-to-use aqueous solution works with narrow gauge needles and pen systems. DepoFoam membrane components are natural, well-tolerated, and cleared by normal metabolic pathways. DepoFoam permits systemicdelivery of
PACIRA BIOSCIENCES ANNOUNCES INVESTMENT IN SPINE BIOPHARMA -- Supports clinical advancement of lead candidate, Remedisc, for degenerative disc disease --PARSIPPANY, N.J., April 20, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced a $3 million investment in Spine BioPharma in the form of a convertible note. HOME | PACIRAABOUT USCOMMITMENTPRODUCTSPARTNERSHIPSNEWSEVENTS Learn More. Our iovera ° system is an FDA-approved handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targeted nerves, interrupting the nerve’s ability to transmit a pain signal. Results can be felt immediately after iovera ° treatment with pain relief that can last three months,and in some
NEW PRODUCTS PAGE
Products. EXPAREL® (bupivacaine liposome injectable suspension) is a local analgesic administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain. *. The ioverao system is a handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targetedIOVERA | PACIRA
ioveraº allows health care providers to control pain by delivering precise, controlled doses of cold temperature to a targeted nerve The ioveraº technology represents a revolutionary cryotherapy platform The ioveraº system is a novel, FDA-approved non-opioid treatment that alleviates pain through a mechanism known as cryoanalgesia, which applies intensely focused cold therapy to a specificCONTACT PACIRA
Contact Us CONTACT PACIRA. × Science Center Campus. 10410 Science Center Drive San Diego, CA 92121 (858) 625 2424PRODUCTS | PACIRA
EXPAREL® (bupivacaine liposome injectable suspension) is changing the way we treat postsurgical pain Low- or no-opioid pain control is possible with EXPAREL EXPAREL is a local anesthetic administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain.CAREERS | PACIRA
Pacira BioSciences, Inc. is an Equal Opportunity Employer.All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, or protected veteran status and will INVESTORS | PACIRA BIOSCIENCES, INC. Pacira BioSciences at the 2021 Jefferies Virtual Healthcare Conference. Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of new pharmaceutical products, based on its proprietary DepoFoam® drug delivery technology, for use in hospitals and ambulatory surgerycenters.
INNOVATION DASHBOARD Pacira Innovation Hub The Innovation Hub features on-demand education covering a broad spectrum of topics designed to stimulate conversation and spark novel thinking in health care. Use the filters below to find the materials you are looking for or explore our Pacira Podcasts.DEPOFOAM | PACIRA
DepoFoam offers flexible delivery and can be designed to offer an immediate-release dose followed by sustained delivery. The ready-to-use aqueous solution works with narrow gauge needles and pen systems. DepoFoam membrane components are natural, well-tolerated, and cleared by normal metabolic pathways. DepoFoam permits systemicdelivery of
PACIRA BIOSCIENCES ANNOUNCES INVESTMENT IN SPINE BIOPHARMA -- Supports clinical advancement of lead candidate, Remedisc, for degenerative disc disease --PARSIPPANY, N.J., April 20, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced a $3 million investment in Spine BioPharma in the form of a convertible note.ABOUT US | PACIRA
Pacira is the leading provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving patient outcomes We’re working to meet the needs of health care practitioners and their patients Our in-depth knowledge of non-opioid pain management, coupled with our passion for delivering improved patient care, drives our commitment to providing solutionsCONTACT PACIRA
Contact Us CONTACT PACIRA. × Science Center Campus. 10410 Science Center Drive San Diego, CA 92121 (858) 625 2424 INNOVATION DASHBOARD Pacira Innovation Hub The Innovation Hub features on-demand education covering a broad spectrum of topics designed to stimulate conversation and spark novel thinking in health care. Use the filters below to find the materials you are looking for or explore our Pacira Podcasts.MEDICAL MISSION
Introduction to Pacira. Pacira BioSciences, Inc. is committed to improving patient care through support of medical missions and charitable contributions aimed at underserved populations in low and middle income communities. Pacira supports recognized, independent, not-for-profit organizations, foundations, patient advocacyorganizations
PACIRA IN THE NEWS
Pacira BioSciences Reports Preliminary Net Product Sales of $44.6 Million for April 2021. 05/11/21. Pacira BioSciences Announces Notice of Allowance of New Patent for EXPAREL. 05/18/21. Pacira BioSciences to Present at the 2021 RBC Capital Markets Global Healthcare Conference. 05/12/21. Pacira BioSciences Reports Preliminary NetProduct Sales
PACIRA BIOSCIENCES REPORTS PRELIMINARY NET PRODUCT SALES April 2021 EXPAREL average daily sales were 449% of April 2020. PARSIPPANY, N.J., May 11, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited net product sales of EXPAREL ® (bupivacaine liposome injectable suspension) and iovera° of $43.1 PACIRA REPORTS RECORD REVENUE FOR 2020 OF $429.6 MILLION -- EXPAREL average daily sales at 109% of the prior year for the fourth quarter and 111% of the prior year for the month of December --PARSIPPANY, N.J., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the leading provider of innovative non-opioid pain management options, today reported preliminary unaudited net revenue of $429.6 million for 2020, a 2.0% increaseBOARD OF DIRECTORS
In June 2013, Mr. Stack was appointed as the Chairman of our board of directors. Mr. Stack was Managing Director of MPM Capital, a private equity firm, from 2005 through March 2017 and has been a Managing Partner of Stack Pharmaceuticals, Inc., a commercialization, marketing, and strategy firm, since 1998. From 2001 to 2004, he wasPresident
PACIRA BIOSCIENCES LAUNCHES NATIONAL REGIONAL ANESTHESIA The initiative aims to educate clinicians on ultrasound-guided regional approaches to manage postsurgical pain. PARSIPPANY, N.J., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), a leading provider of innovative non-opioid pain management options, today announced a collaboration with Envision Physician Services to train anesthesiology clinicians on PACIRA ANNOUNCES PUBLICATION OF PHASE 4 STUDY OF EXPAREL The Investor Relations website contains information about Pacira BioSciences, Inc.'s business for stockholders, potential investors, and financial analysts. HOME | PACIRAABOUT USCOMMITMENTPRODUCTSPARTNERSHIPSNEWSEVENTS Learn More. Our iovera ° system is an FDA-approved handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targeted nerves, interrupting the nerve’s ability to transmit a pain signal. Results can be felt immediately after iovera ° treatment with pain relief that can last three months,and in some
NEW PRODUCTS PAGE
Products. EXPAREL® (bupivacaine liposome injectable suspension) is a local analgesic administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain. *. The ioverao system is a handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targetedIOVERA | PACIRA
ioveraº allows health care providers to control pain by delivering precise, controlled doses of cold temperature to a targeted nerve The ioveraº technology represents a revolutionary cryotherapy platform The ioveraº system is a novel, FDA-approved non-opioid treatment that alleviates pain through a mechanism known as cryoanalgesia, which applies intensely focused cold therapy to a specificCONTACT PACIRA
Contact Us CONTACT PACIRA. × Science Center Campus. 10410 Science Center Drive San Diego, CA 92121 (858) 625 2424PRODUCTS | PACIRA
EXPAREL® (bupivacaine liposome injectable suspension) is changing the way we treat postsurgical pain Low- or no-opioid pain control is possible with EXPAREL EXPAREL is a local anesthetic administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain.CAREERS | PACIRA
Pacira BioSciences, Inc. is an Equal Opportunity Employer.All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, or protected veteran status and will INVESTORS | PACIRA BIOSCIENCES, INC. Pacira BioSciences at the 2021 Jefferies Virtual Healthcare Conference. Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of new pharmaceutical products, based on its proprietary DepoFoam® drug delivery technology, for use in hospitals and ambulatory surgerycenters.
INNOVATION DASHBOARD Pacira Innovation Hub The Innovation Hub features on-demand education covering a broad spectrum of topics designed to stimulate conversation and spark novel thinking in health care. Use the filters below to find the materials you are looking for or explore our Pacira Podcasts.DEPOFOAM | PACIRA
DepoFoam offers flexible delivery and can be designed to offer an immediate-release dose followed by sustained delivery. The ready-to-use aqueous solution works with narrow gauge needles and pen systems. DepoFoam membrane components are natural, well-tolerated, and cleared by normal metabolic pathways. DepoFoam permits systemicdelivery of
PACIRA BIOSCIENCES ANNOUNCES INVESTMENT IN SPINE BIOPHARMA -- Supports clinical advancement of lead candidate, Remedisc, for degenerative disc disease --PARSIPPANY, N.J., April 20, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced a $3 million investment in Spine BioPharma in the form of a convertible note. HOME | PACIRAABOUT USCOMMITMENTPRODUCTSPARTNERSHIPSNEWSEVENTS Learn More. Our iovera ° system is an FDA-approved handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targeted nerves, interrupting the nerve’s ability to transmit a pain signal. Results can be felt immediately after iovera ° treatment with pain relief that can last three months,and in some
NEW PRODUCTS PAGE
Products. EXPAREL® (bupivacaine liposome injectable suspension) is a local analgesic administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain. *. The ioverao system is a handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targetedIOVERA | PACIRA
ioveraº allows health care providers to control pain by delivering precise, controlled doses of cold temperature to a targeted nerve The ioveraº technology represents a revolutionary cryotherapy platform The ioveraº system is a novel, FDA-approved non-opioid treatment that alleviates pain through a mechanism known as cryoanalgesia, which applies intensely focused cold therapy to a specificCONTACT PACIRA
Contact Us CONTACT PACIRA. × Science Center Campus. 10410 Science Center Drive San Diego, CA 92121 (858) 625 2424PRODUCTS | PACIRA
EXPAREL® (bupivacaine liposome injectable suspension) is changing the way we treat postsurgical pain Low- or no-opioid pain control is possible with EXPAREL EXPAREL is a local anesthetic administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain.CAREERS | PACIRA
Pacira BioSciences, Inc. is an Equal Opportunity Employer.All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, or protected veteran status and will INVESTORS | PACIRA BIOSCIENCES, INC. Pacira BioSciences at the 2021 Jefferies Virtual Healthcare Conference. Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of new pharmaceutical products, based on its proprietary DepoFoam® drug delivery technology, for use in hospitals and ambulatory surgerycenters.
INNOVATION DASHBOARD Pacira Innovation Hub The Innovation Hub features on-demand education covering a broad spectrum of topics designed to stimulate conversation and spark novel thinking in health care. Use the filters below to find the materials you are looking for or explore our Pacira Podcasts.DEPOFOAM | PACIRA
DepoFoam offers flexible delivery and can be designed to offer an immediate-release dose followed by sustained delivery. The ready-to-use aqueous solution works with narrow gauge needles and pen systems. DepoFoam membrane components are natural, well-tolerated, and cleared by normal metabolic pathways. DepoFoam permits systemicdelivery of
PACIRA BIOSCIENCES ANNOUNCES INVESTMENT IN SPINE BIOPHARMA -- Supports clinical advancement of lead candidate, Remedisc, for degenerative disc disease --PARSIPPANY, N.J., April 20, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced a $3 million investment in Spine BioPharma in the form of a convertible note.ABOUT US | PACIRA
Pacira is the leading provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving patient outcomes We’re working to meet the needs of health care practitioners and their patients Our in-depth knowledge of non-opioid pain management, coupled with our passion for delivering improved patient care, drives our commitment to providing solutionsCONTACT PACIRA
Contact Us CONTACT PACIRA. × Science Center Campus. 10410 Science Center Drive San Diego, CA 92121 (858) 625 2424 INNOVATION DASHBOARD Pacira Innovation Hub The Innovation Hub features on-demand education covering a broad spectrum of topics designed to stimulate conversation and spark novel thinking in health care. Use the filters below to find the materials you are looking for or explore our Pacira Podcasts.MEDICAL MISSION
Introduction to Pacira. Pacira BioSciences, Inc. is committed to improving patient care through support of medical missions and charitable contributions aimed at underserved populations in low and middle income communities. Pacira supports recognized, independent, not-for-profit organizations, foundations, patient advocacyorganizations
PACIRA IN THE NEWS
Pacira BioSciences Reports Preliminary Net Product Sales of $44.6 Million for April 2021. 05/11/21. Pacira BioSciences Announces Notice of Allowance of New Patent for EXPAREL. 05/18/21. Pacira BioSciences to Present at the 2021 RBC Capital Markets Global Healthcare Conference. 05/12/21. Pacira BioSciences Reports Preliminary NetProduct Sales
PACIRA BIOSCIENCES REPORTS PRELIMINARY NET PRODUCT SALES April 2021 EXPAREL average daily sales were 449% of April 2020. PARSIPPANY, N.J., May 11, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited net product sales of EXPAREL ® (bupivacaine liposome injectable suspension) and iovera° of $43.1 PACIRA REPORTS RECORD REVENUE FOR 2020 OF $429.6 MILLION -- EXPAREL average daily sales at 109% of the prior year for the fourth quarter and 111% of the prior year for the month of December --PARSIPPANY, N.J., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the leading provider of innovative non-opioid pain management options, today reported preliminary unaudited net revenue of $429.6 million for 2020, a 2.0% increaseBOARD OF DIRECTORS
In June 2013, Mr. Stack was appointed as the Chairman of our board of directors. Mr. Stack was Managing Director of MPM Capital, a private equity firm, from 2005 through March 2017 and has been a Managing Partner of Stack Pharmaceuticals, Inc., a commercialization, marketing, and strategy firm, since 1998. From 2001 to 2004, he wasPresident
PACIRA BIOSCIENCES LAUNCHES NATIONAL REGIONAL ANESTHESIA The initiative aims to educate clinicians on ultrasound-guided regional approaches to manage postsurgical pain. PARSIPPANY, N.J., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), a leading provider of innovative non-opioid pain management options, today announced a collaboration with Envision Physician Services to train anesthesiology clinicians on PACIRA ANNOUNCES PUBLICATION OF PHASE 4 STUDY OF EXPAREL The Investor Relations website contains information about Pacira BioSciences, Inc.'s business for stockholders, potential investors, and financial analysts. HOME | PACIRAABOUT USCOMMITMENTPRODUCTSPARTNERSHIPSNEWSEVENTS Learn More. Our iovera ° system is an FDA-approved handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targeted nerves, interrupting the nerve’s ability to transmit a pain signal. Results can be felt immediately after iovera ° treatment with pain relief that can last three months,and in some
NEW PRODUCTS PAGE
Products. EXPAREL® (bupivacaine liposome injectable suspension) is a local analgesic administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain. *. The ioverao system is a handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targetedABOUT US | PACIRA
Pacira is the leading provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving patient outcomes We’re working to meet the needs of health care practitioners and their patients Our in-depth knowledge of non-opioid pain management, coupled with our passion for delivering improved patient care, drives our commitment to providing solutionsCAREERS | PACIRA
Pacira BioSciences, Inc. is an Equal Opportunity Employer.All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, or protected veteran status and willPRODUCTS | PACIRA
EXPAREL® (bupivacaine liposome injectable suspension) is changing the way we treat postsurgical pain Low- or no-opioid pain control is possible with EXPAREL EXPAREL is a local anesthetic administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain.CONTACT PACIRA
Contact Us CONTACT PACIRA. × Science Center Campus. 10410 Science Center Drive San Diego, CA 92121 (858) 625 2424IOVERA | PACIRA
ioveraº allows health care providers to control pain by delivering precise, controlled doses of cold temperature to a targeted nerve The ioveraº technology represents a revolutionary cryotherapy platform The ioveraº system is a novel, FDA-approved non-opioid treatment that alleviates pain through a mechanism known as cryoanalgesia, which applies intensely focused cold therapy to a specific INVESTORS | PACIRA BIOSCIENCES, INC. Pacira BioSciences at the 2021 Jefferies Virtual Healthcare Conference. Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of new pharmaceutical products, based on its proprietary DepoFoam® drug delivery technology, for use in hospitals and ambulatory surgerycenters.
HIGHLIGHTS OF PRESCRIBING INFORMATION EXPAREL. • In patients undergoing bunionectomy, a total of 106 mg (8 mL) of EXPAREL was administered, with 7 mL infiltrated into the tissues surrounding the osteotomy, and 1 mL PACIRA BIOSCIENCES LAUNCHES NATIONAL REGIONAL ANESTHESIA The initiative aims to educate clinicians on ultrasound-guided regional approaches to manage postsurgical pain. PARSIPPANY, N.J., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), a leading provider of innovative non-opioid pain management options, today announced a collaboration with Envision Physician Services to train anesthesiology clinicians on HOME | PACIRAABOUT USCOMMITMENTPRODUCTSPARTNERSHIPSNEWSEVENTS Learn More. Our iovera ° system is an FDA-approved handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targeted nerves, interrupting the nerve’s ability to transmit a pain signal. Results can be felt immediately after iovera ° treatment with pain relief that can last three months,and in some
NEW PRODUCTS PAGE
Products. EXPAREL® (bupivacaine liposome injectable suspension) is a local analgesic administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain. *. The ioverao system is a handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targetedABOUT US | PACIRA
Pacira is the leading provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving patient outcomes We’re working to meet the needs of health care practitioners and their patients Our in-depth knowledge of non-opioid pain management, coupled with our passion for delivering improved patient care, drives our commitment to providing solutionsCAREERS | PACIRA
Pacira BioSciences, Inc. is an Equal Opportunity Employer.All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, or protected veteran status and willCONTACT PACIRA
Contact Us CONTACT PACIRA. × Science Center Campus. 10410 Science Center Drive San Diego, CA 92121 (858) 625 2424PRODUCTS | PACIRA
EXPAREL® (bupivacaine liposome injectable suspension) is changing the way we treat postsurgical pain Low- or no-opioid pain control is possible with EXPAREL EXPAREL is a local anesthetic administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain.IOVERA | PACIRA
ioveraº allows health care providers to control pain by delivering precise, controlled doses of cold temperature to a targeted nerve The ioveraº technology represents a revolutionary cryotherapy platform The ioveraº system is a novel, FDA-approved non-opioid treatment that alleviates pain through a mechanism known as cryoanalgesia, which applies intensely focused cold therapy to a specific INVESTORS | PACIRA BIOSCIENCES, INC. Pacira BioSciences at the 2021 Jefferies Virtual Healthcare Conference. Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of new pharmaceutical products, based on its proprietary DepoFoam® drug delivery technology, for use in hospitals and ambulatory surgerycenters.
HIGHLIGHTS OF PRESCRIBING INFORMATION EXPAREL. • In patients undergoing bunionectomy, a total of 106 mg (8 mL) of EXPAREL was administered, with 7 mL infiltrated into the tissues surrounding the osteotomy, and 1 mL PACIRA BIOSCIENCES LAUNCHES NATIONAL REGIONAL ANESTHESIA The initiative aims to educate clinicians on ultrasound-guided regional approaches to manage postsurgical pain. PARSIPPANY, N.J., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), a leading provider of innovative non-opioid pain management options, today announced a collaboration with Envision Physician Services to train anesthesiology clinicians onCONTACT PACIRA
Contact Us CONTACT PACIRA. × Science Center Campus. 10410 Science Center Drive San Diego, CA 92121 (858) 625 2424 INNOVATION DASHBOARD Pacira Innovation Hub The Innovation Hub features on-demand education covering a broad spectrum of topics designed to stimulate conversation and spark novel thinking in health care. Use the filters below to find the materials you are looking for or explore our Pacira Podcasts.DEPOFOAM | PACIRA
DepoFoam offers flexible delivery and can be designed to offer an immediate-release dose followed by sustained delivery. The ready-to-use aqueous solution works with narrow gauge needles and pen systems. DepoFoam membrane components are natural, well-tolerated, and cleared by normal metabolic pathways. DepoFoam permits systemicdelivery of
PACIRA LEGAL INFORMATION Pacira BioSciences, Inc. has prepared this information in good faith based on current information reasonably available. No liability whatsoever is accepted and no representation, warranty or undertaking, express or implied, is or will be made by Pacira or any of Pacira's affiliates, or any of their respective agents, directors, officers, employees, advisers, or representatives ("Agents"), forPACIRA IN THE NEWS
Pacira BioSciences Reports Preliminary Net Product Sales of $44.6 Million for April 2021. 05/11/21. Pacira BioSciences Announces Notice of Allowance of New Patent for EXPAREL. 05/18/21. Pacira BioSciences to Present at the 2021 RBC Capital Markets Global Healthcare Conference. 05/12/21. Pacira BioSciences Reports Preliminary NetProduct Sales
PACIRA BIOSCIENCES ANNOUNCES INVESTMENT IN SPINE BIOPHARMA -- Supports clinical advancement of lead candidate, Remedisc, for degenerative disc disease --PARSIPPANY, N.J., April 20, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced a $3 million investment in Spine BioPharma in the form of a convertible note. USING EXPAREL® (BUPIVACAINE LIPOSOME INJECTABLE A cross functional panel discusses data, implementation of, and education considerations for EXPAREL. B. Wycke Baker, MD, MHA; Elizabeth Cherot, MBA, MD, FACOG PACIRA BIOSCIENCES LAUNCHES NATIONAL REGIONAL ANESTHESIA The initiative aims to educate clinicians on ultrasound-guided regional approaches to manage postsurgical pain. PARSIPPANY, N.J., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), a leading provider of innovative non-opioid pain management options, today announced a collaboration with Envision Physician Services to train anesthesiology clinicians on PACIRA BIOSCIENCES ANNOUNCES EQUITY INVESTMENT IN Supports Development of Promising Gene Therapy Platform for Osteoarthritis. PARSIPPANY, N.J., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the leading provider of innovative non-opioid pain management options, today announced that the company will lead an equity investment in GeneQuine Biotherapeutics GmbH. NEWS RELEASE FOR IMMEDIATE RELEASE NEWS RELEASE FOR IMMEDIATE RELEASE Pacira BioSciences Seeks Court Injunction to Protect Clinical Integrity of EXPAREL in the Face of Scientifically Flawed and Misleading Information Published in Anesthesiology Complaint challenges the American Society of Anesthesiologists for promoting biased, HOME | PACIRAABOUT USCOMMITMENTPRODUCTSPARTNERSHIPSNEWSEVENTS Learn More. Our iovera ° system is an FDA-approved handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targeted nerves, interrupting the nerve’s ability to transmit a pain signal. Results can be felt immediately after iovera ° treatment with pain relief that can last three months,and in some
NEW PRODUCTS PAGE
Products. EXPAREL® (bupivacaine liposome injectable suspension) is a local analgesic administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain. *. The ioverao system is a handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targetedABOUT US | PACIRA
Pacira is the leading provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving patient outcomes We’re working to meet the needs of health care practitioners and their patients Our in-depth knowledge of non-opioid pain management, coupled with our passion for delivering improved patient care, drives our commitment to providing solutionsCAREERS | PACIRA
Pacira BioSciences, Inc. is an Equal Opportunity Employer.All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, or protected veteran status and willPRODUCTS | PACIRA
EXPAREL® (bupivacaine liposome injectable suspension) is changing the way we treat postsurgical pain Low- or no-opioid pain control is possible with EXPAREL EXPAREL is a local anesthetic administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain.CONTACT PACIRA
Contact Us CONTACT PACIRA. × Science Center Campus. 10410 Science Center Drive San Diego, CA 92121 (858) 625 2424IOVERA | PACIRA
ioveraº allows health care providers to control pain by delivering precise, controlled doses of cold temperature to a targeted nerve The ioveraº technology represents a revolutionary cryotherapy platform The ioveraº system is a novel, FDA-approved non-opioid treatment that alleviates pain through a mechanism known as cryoanalgesia, which applies intensely focused cold therapy to a specific INVESTORS | PACIRA BIOSCIENCES, INC. Pacira BioSciences at the 2021 Jefferies Virtual Healthcare Conference. Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of new pharmaceutical products, based on its proprietary DepoFoam® drug delivery technology, for use in hospitals and ambulatory surgerycenters.
HIGHLIGHTS OF PRESCRIBING INFORMATION EXPAREL. • In patients undergoing bunionectomy, a total of 106 mg (8 mL) of EXPAREL was administered, with 7 mL infiltrated into the tissues surrounding the osteotomy, and 1 mL PACIRA BIOSCIENCES LAUNCHES NATIONAL REGIONAL ANESTHESIA The initiative aims to educate clinicians on ultrasound-guided regional approaches to manage postsurgical pain. PARSIPPANY, N.J., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), a leading provider of innovative non-opioid pain management options, today announced a collaboration with Envision Physician Services to train anesthesiology clinicians on HOME | PACIRAABOUT USCOMMITMENTPRODUCTSPARTNERSHIPSNEWSEVENTS Learn More. Our iovera ° system is an FDA-approved handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targeted nerves, interrupting the nerve’s ability to transmit a pain signal. Results can be felt immediately after iovera ° treatment with pain relief that can last three months,and in some
NEW PRODUCTS PAGE
Products. EXPAREL® (bupivacaine liposome injectable suspension) is a local analgesic administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain. *. The ioverao system is a handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targetedABOUT US | PACIRA
Pacira is the leading provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving patient outcomes We’re working to meet the needs of health care practitioners and their patients Our in-depth knowledge of non-opioid pain management, coupled with our passion for delivering improved patient care, drives our commitment to providing solutionsCAREERS | PACIRA
Pacira BioSciences, Inc. is an Equal Opportunity Employer.All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, or protected veteran status and willPRODUCTS | PACIRA
EXPAREL® (bupivacaine liposome injectable suspension) is changing the way we treat postsurgical pain Low- or no-opioid pain control is possible with EXPAREL EXPAREL is a local anesthetic administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain.CONTACT PACIRA
Contact Us CONTACT PACIRA. × Science Center Campus. 10410 Science Center Drive San Diego, CA 92121 (858) 625 2424IOVERA | PACIRA
ioveraº allows health care providers to control pain by delivering precise, controlled doses of cold temperature to a targeted nerve The ioveraº technology represents a revolutionary cryotherapy platform The ioveraº system is a novel, FDA-approved non-opioid treatment that alleviates pain through a mechanism known as cryoanalgesia, which applies intensely focused cold therapy to a specific INVESTORS | PACIRA BIOSCIENCES, INC. Pacira BioSciences at the 2021 Jefferies Virtual Healthcare Conference. Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of new pharmaceutical products, based on its proprietary DepoFoam® drug delivery technology, for use in hospitals and ambulatory surgerycenters.
HIGHLIGHTS OF PRESCRIBING INFORMATION EXPAREL. • In patients undergoing bunionectomy, a total of 106 mg (8 mL) of EXPAREL was administered, with 7 mL infiltrated into the tissues surrounding the osteotomy, and 1 mL PACIRA BIOSCIENCES LAUNCHES NATIONAL REGIONAL ANESTHESIA The initiative aims to educate clinicians on ultrasound-guided regional approaches to manage postsurgical pain. PARSIPPANY, N.J., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), a leading provider of innovative non-opioid pain management options, today announced a collaboration with Envision Physician Services to train anesthesiology clinicians onCONTACT PACIRA
Contact Us CONTACT PACIRA. × Science Center Campus. 10410 Science Center Drive San Diego, CA 92121 (858) 625 2424 INNOVATION DASHBOARD Pacira Innovation Hub The Innovation Hub features on-demand education covering a broad spectrum of topics designed to stimulate conversation and spark novel thinking in health care. Use the filters below to find the materials you are looking for or explore our Pacira Podcasts.DEPOFOAM | PACIRA
DepoFoam offers flexible delivery and can be designed to offer an immediate-release dose followed by sustained delivery. The ready-to-use aqueous solution works with narrow gauge needles and pen systems. DepoFoam membrane components are natural, well-tolerated, and cleared by normal metabolic pathways. DepoFoam permits systemicdelivery of
PACIRA LEGAL INFORMATION Pacira BioSciences, Inc. has prepared this information in good faith based on current information reasonably available. No liability whatsoever is accepted and no representation, warranty or undertaking, express or implied, is or will be made by Pacira or any of Pacira's affiliates, or any of their respective agents, directors, officers, employees, advisers, or representatives ("Agents"), forPACIRA IN THE NEWS
Pacira BioSciences Reports Preliminary Net Product Sales of $44.6 Million for April 2021. 05/11/21. Pacira BioSciences Announces Notice of Allowance of New Patent for EXPAREL. 05/18/21. Pacira BioSciences to Present at the 2021 RBC Capital Markets Global Healthcare Conference. 05/12/21. Pacira BioSciences Reports Preliminary NetProduct Sales
PACIRA BIOSCIENCES ANNOUNCES INVESTMENT IN SPINE BIOPHARMA -- Supports clinical advancement of lead candidate, Remedisc, for degenerative disc disease --PARSIPPANY, N.J., April 20, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced a $3 million investment in Spine BioPharma in the form of a convertible note. USING EXPAREL® (BUPIVACAINE LIPOSOME INJECTABLE A cross functional panel discusses data, implementation of, and education considerations for EXPAREL. B. Wycke Baker, MD, MHA; Elizabeth Cherot, MBA, MD, FACOG PACIRA BIOSCIENCES LAUNCHES NATIONAL REGIONAL ANESTHESIA The initiative aims to educate clinicians on ultrasound-guided regional approaches to manage postsurgical pain. PARSIPPANY, N.J., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), a leading provider of innovative non-opioid pain management options, today announced a collaboration with Envision Physician Services to train anesthesiology clinicians on PACIRA BIOSCIENCES ANNOUNCES EQUITY INVESTMENT IN Supports Development of Promising Gene Therapy Platform for Osteoarthritis. PARSIPPANY, N.J., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the leading provider of innovative non-opioid pain management options, today announced that the company will lead an equity investment in GeneQuine Biotherapeutics GmbH. NEWS RELEASE FOR IMMEDIATE RELEASE NEWS RELEASE FOR IMMEDIATE RELEASE Pacira BioSciences Seeks Court Injunction to Protect Clinical Integrity of EXPAREL in the Face of Scientifically Flawed and Misleading Information Published in Anesthesiology Complaint challenges the American Society of Anesthesiologists for promoting biased, HOME | PACIRAABOUT USCOMMITMENTPRODUCTSPARTNERSHIPSNEWSEVENTS Learn More. Our iovera ° system is an FDA-approved handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targeted nerves, interrupting the nerve’s ability to transmit a pain signal. Results can be felt immediately after iovera ° treatment with pain relief that can last three months,and in some
NEW PRODUCTS PAGE
Products. EXPAREL® (bupivacaine liposome injectable suspension) is a local analgesic administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain. *. The ioverao system is a handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targetedABOUT US | PACIRA
Pacira is the leading provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving patient outcomes We’re working to meet the needs of health care practitioners and their patients Our in-depth knowledge of non-opioid pain management, coupled with our passion for delivering improved patient care, drives our commitment to providing solutionsCAREERS | PACIRA
Pacira BioSciences, Inc. is an Equal Opportunity Employer.All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, or protected veteran status and willPRODUCTS | PACIRA
EXPAREL® (bupivacaine liposome injectable suspension) is changing the way we treat postsurgical pain Low- or no-opioid pain control is possible with EXPAREL EXPAREL is a local anesthetic administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain.CONTACT PACIRA
Contact Us CONTACT PACIRA. × Science Center Campus. 10410 Science Center Drive San Diego, CA 92121 (858) 625 2424IOVERA | PACIRA
ioveraº allows health care providers to control pain by delivering precise, controlled doses of cold temperature to a targeted nerve The ioveraº technology represents a revolutionary cryotherapy platform The ioveraº system is a novel, FDA-approved non-opioid treatment that alleviates pain through a mechanism known as cryoanalgesia, which applies intensely focused cold therapy to a specific INVESTORS | PACIRA BIOSCIENCES, INC. Pacira BioSciences at the 2021 Jefferies Virtual Healthcare Conference. Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of new pharmaceutical products, based on its proprietary DepoFoam® drug delivery technology, for use in hospitals and ambulatory surgerycenters.
HIGHLIGHTS OF PRESCRIBING INFORMATION EXPAREL. • In patients undergoing bunionectomy, a total of 106 mg (8 mL) of EXPAREL was administered, with 7 mL infiltrated into the tissues surrounding the osteotomy, and 1 mL PACIRA BIOSCIENCES LAUNCHES NATIONAL REGIONAL ANESTHESIA The initiative aims to educate clinicians on ultrasound-guided regional approaches to manage postsurgical pain. PARSIPPANY, N.J., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), a leading provider of innovative non-opioid pain management options, today announced a collaboration with Envision Physician Services to train anesthesiology clinicians on HOME | PACIRAABOUT USCOMMITMENTPRODUCTSPARTNERSHIPSNEWSEVENTS Learn More. Our iovera ° system is an FDA-approved handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targeted nerves, interrupting the nerve’s ability to transmit a pain signal. Results can be felt immediately after iovera ° treatment with pain relief that can last three months,and in some
NEW PRODUCTS PAGE
Products. EXPAREL® (bupivacaine liposome injectable suspension) is a local analgesic administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain. *. The ioverao system is a handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targetedABOUT US | PACIRA
Pacira is the leading provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving patient outcomes We’re working to meet the needs of health care practitioners and their patients Our in-depth knowledge of non-opioid pain management, coupled with our passion for delivering improved patient care, drives our commitment to providing solutionsCAREERS | PACIRA
Pacira BioSciences, Inc. is an Equal Opportunity Employer.All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, or protected veteran status and willPRODUCTS | PACIRA
EXPAREL® (bupivacaine liposome injectable suspension) is changing the way we treat postsurgical pain Low- or no-opioid pain control is possible with EXPAREL EXPAREL is a local anesthetic administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain.CONTACT PACIRA
Contact Us CONTACT PACIRA. × Science Center Campus. 10410 Science Center Drive San Diego, CA 92121 (858) 625 2424IOVERA | PACIRA
ioveraº allows health care providers to control pain by delivering precise, controlled doses of cold temperature to a targeted nerve The ioveraº technology represents a revolutionary cryotherapy platform The ioveraº system is a novel, FDA-approved non-opioid treatment that alleviates pain through a mechanism known as cryoanalgesia, which applies intensely focused cold therapy to a specific INVESTORS | PACIRA BIOSCIENCES, INC. Pacira BioSciences at the 2021 Jefferies Virtual Healthcare Conference. Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of new pharmaceutical products, based on its proprietary DepoFoam® drug delivery technology, for use in hospitals and ambulatory surgerycenters.
HIGHLIGHTS OF PRESCRIBING INFORMATION EXPAREL. • In patients undergoing bunionectomy, a total of 106 mg (8 mL) of EXPAREL was administered, with 7 mL infiltrated into the tissues surrounding the osteotomy, and 1 mL PACIRA BIOSCIENCES LAUNCHES NATIONAL REGIONAL ANESTHESIA The initiative aims to educate clinicians on ultrasound-guided regional approaches to manage postsurgical pain. PARSIPPANY, N.J., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), a leading provider of innovative non-opioid pain management options, today announced a collaboration with Envision Physician Services to train anesthesiology clinicians onCONTACT PACIRA
Contact Us CONTACT PACIRA. × Science Center Campus. 10410 Science Center Drive San Diego, CA 92121 (858) 625 2424 INNOVATION DASHBOARD Pacira Innovation Hub The Innovation Hub features on-demand education covering a broad spectrum of topics designed to stimulate conversation and spark novel thinking in health care. Use the filters below to find the materials you are looking for or explore our Pacira Podcasts.DEPOFOAM | PACIRA
DepoFoam offers flexible delivery and can be designed to offer an immediate-release dose followed by sustained delivery. The ready-to-use aqueous solution works with narrow gauge needles and pen systems. DepoFoam membrane components are natural, well-tolerated, and cleared by normal metabolic pathways. DepoFoam permits systemicdelivery of
PACIRA LEGAL INFORMATION Pacira BioSciences, Inc. has prepared this information in good faith based on current information reasonably available. No liability whatsoever is accepted and no representation, warranty or undertaking, express or implied, is or will be made by Pacira or any of Pacira's affiliates, or any of their respective agents, directors, officers, employees, advisers, or representatives ("Agents"), forPACIRA IN THE NEWS
Pacira BioSciences Reports Preliminary Net Product Sales of $44.6 Million for April 2021. 05/11/21. Pacira BioSciences Announces Notice of Allowance of New Patent for EXPAREL. 05/18/21. Pacira BioSciences to Present at the 2021 RBC Capital Markets Global Healthcare Conference. 05/12/21. Pacira BioSciences Reports Preliminary NetProduct Sales
PACIRA BIOSCIENCES ANNOUNCES INVESTMENT IN SPINE BIOPHARMA -- Supports clinical advancement of lead candidate, Remedisc, for degenerative disc disease --PARSIPPANY, N.J., April 20, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced a $3 million investment in Spine BioPharma in the form of a convertible note. USING EXPAREL® (BUPIVACAINE LIPOSOME INJECTABLE A cross functional panel discusses data, implementation of, and education considerations for EXPAREL. B. Wycke Baker, MD, MHA; Elizabeth Cherot, MBA, MD, FACOG PACIRA BIOSCIENCES LAUNCHES NATIONAL REGIONAL ANESTHESIA The initiative aims to educate clinicians on ultrasound-guided regional approaches to manage postsurgical pain. PARSIPPANY, N.J., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), a leading provider of innovative non-opioid pain management options, today announced a collaboration with Envision Physician Services to train anesthesiology clinicians on PACIRA BIOSCIENCES ANNOUNCES EQUITY INVESTMENT IN Supports Development of Promising Gene Therapy Platform for Osteoarthritis. PARSIPPANY, N.J., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the leading provider of innovative non-opioid pain management options, today announced that the company will lead an equity investment in GeneQuine Biotherapeutics GmbH. NEWS RELEASE FOR IMMEDIATE RELEASE NEWS RELEASE FOR IMMEDIATE RELEASE Pacira BioSciences Seeks Court Injunction to Protect Clinical Integrity of EXPAREL in the Face of Scientifically Flawed and Misleading Information Published in Anesthesiology Complaint challenges the American Society of Anesthesiologists for promoting biased, HOME | PACIRAABOUT USCOMMITMENTPRODUCTSPARTNERSHIPSNEWSEVENTS Learn More. Our iovera ° system is an FDA-approved handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targeted nerves, interrupting the nerve’s ability to transmit a pain signal. Results can be felt immediately after iovera ° treatment with pain relief that can last three months,and in some
NEW PRODUCTS PAGE
Products. EXPAREL® (bupivacaine liposome injectable suspension) is a local analgesic administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain. *. The ioverao system is a handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targetedABOUT US | PACIRA
Pacira is the leading provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving patient outcomes We’re working to meet the needs of health care practitioners and their patients Our in-depth knowledge of non-opioid pain management, coupled with our passion for delivering improved patient care, drives our commitment to providing solutionsCAREERS | PACIRA
Pacira BioSciences, Inc. is an Equal Opportunity Employer.All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, or protected veteran status and willPRODUCTS | PACIRA
EXPAREL® (bupivacaine liposome injectable suspension) is changing the way we treat postsurgical pain Low- or no-opioid pain control is possible with EXPAREL EXPAREL is a local anesthetic administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain.CONTACT PACIRA
Contact Us CONTACT PACIRA. × Science Center Campus. 10410 Science Center Drive San Diego, CA 92121 (858) 625 2424IOVERA | PACIRA
ioveraº allows health care providers to control pain by delivering precise, controlled doses of cold temperature to a targeted nerve The ioveraº technology represents a revolutionary cryotherapy platform The ioveraº system is a novel, FDA-approved non-opioid treatment that alleviates pain through a mechanism known as cryoanalgesia, which applies intensely focused cold therapy to a specific INVESTORS | PACIRA BIOSCIENCES, INC. Pacira BioSciences at the 2021 Jefferies Virtual Healthcare Conference. Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of new pharmaceutical products, based on its proprietary DepoFoam® drug delivery technology, for use in hospitals and ambulatory surgerycenters.
HIGHLIGHTS OF PRESCRIBING INFORMATION EXPAREL. • In patients undergoing bunionectomy, a total of 106 mg (8 mL) of EXPAREL was administered, with 7 mL infiltrated into the tissues surrounding the osteotomy, and 1 mL PACIRA BIOSCIENCES LAUNCHES NATIONAL REGIONAL ANESTHESIA The initiative aims to educate clinicians on ultrasound-guided regional approaches to manage postsurgical pain. PARSIPPANY, N.J., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), a leading provider of innovative non-opioid pain management options, today announced a collaboration with Envision Physician Services to train anesthesiology clinicians on HOME | PACIRAABOUT USCOMMITMENTPRODUCTSPARTNERSHIPSNEWSEVENTS Learn More. Our iovera ° system is an FDA-approved handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targeted nerves, interrupting the nerve’s ability to transmit a pain signal. Results can be felt immediately after iovera ° treatment with pain relief that can last three months,and in some
NEW PRODUCTS PAGE
Products. EXPAREL® (bupivacaine liposome injectable suspension) is a local analgesic administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain. *. The ioverao system is a handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targetedABOUT US | PACIRA
Pacira is the leading provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving patient outcomes We’re working to meet the needs of health care practitioners and their patients Our in-depth knowledge of non-opioid pain management, coupled with our passion for delivering improved patient care, drives our commitment to providing solutionsCAREERS | PACIRA
Pacira BioSciences, Inc. is an Equal Opportunity Employer.All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, or protected veteran status and willPRODUCTS | PACIRA
EXPAREL® (bupivacaine liposome injectable suspension) is changing the way we treat postsurgical pain Low- or no-opioid pain control is possible with EXPAREL EXPAREL is a local anesthetic administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain.CONTACT PACIRA
Contact Us CONTACT PACIRA. × Science Center Campus. 10410 Science Center Drive San Diego, CA 92121 (858) 625 2424IOVERA | PACIRA
ioveraº allows health care providers to control pain by delivering precise, controlled doses of cold temperature to a targeted nerve The ioveraº technology represents a revolutionary cryotherapy platform The ioveraº system is a novel, FDA-approved non-opioid treatment that alleviates pain through a mechanism known as cryoanalgesia, which applies intensely focused cold therapy to a specific INVESTORS | PACIRA BIOSCIENCES, INC. Pacira BioSciences at the 2021 Jefferies Virtual Healthcare Conference. Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of new pharmaceutical products, based on its proprietary DepoFoam® drug delivery technology, for use in hospitals and ambulatory surgerycenters.
HIGHLIGHTS OF PRESCRIBING INFORMATION EXPAREL. • In patients undergoing bunionectomy, a total of 106 mg (8 mL) of EXPAREL was administered, with 7 mL infiltrated into the tissues surrounding the osteotomy, and 1 mL PACIRA BIOSCIENCES LAUNCHES NATIONAL REGIONAL ANESTHESIA The initiative aims to educate clinicians on ultrasound-guided regional approaches to manage postsurgical pain. PARSIPPANY, N.J., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), a leading provider of innovative non-opioid pain management options, today announced a collaboration with Envision Physician Services to train anesthesiology clinicians onCONTACT PACIRA
Contact Us CONTACT PACIRA. × Science Center Campus. 10410 Science Center Drive San Diego, CA 92121 (858) 625 2424 INNOVATION DASHBOARD Pacira Innovation Hub The Innovation Hub features on-demand education covering a broad spectrum of topics designed to stimulate conversation and spark novel thinking in health care. Use the filters below to find the materials you are looking for or explore our Pacira Podcasts.DEPOFOAM | PACIRA
DepoFoam offers flexible delivery and can be designed to offer an immediate-release dose followed by sustained delivery. The ready-to-use aqueous solution works with narrow gauge needles and pen systems. DepoFoam membrane components are natural, well-tolerated, and cleared by normal metabolic pathways. DepoFoam permits systemicdelivery of
PACIRA LEGAL INFORMATION Pacira BioSciences, Inc. has prepared this information in good faith based on current information reasonably available. No liability whatsoever is accepted and no representation, warranty or undertaking, express or implied, is or will be made by Pacira or any of Pacira's affiliates, or any of their respective agents, directors, officers, employees, advisers, or representatives ("Agents"), forPACIRA IN THE NEWS
Pacira BioSciences Reports Preliminary Net Product Sales of $44.6 Million for April 2021. 05/11/21. Pacira BioSciences Announces Notice of Allowance of New Patent for EXPAREL. 05/18/21. Pacira BioSciences to Present at the 2021 RBC Capital Markets Global Healthcare Conference. 05/12/21. Pacira BioSciences Reports Preliminary NetProduct Sales
PACIRA BIOSCIENCES ANNOUNCES INVESTMENT IN SPINE BIOPHARMA -- Supports clinical advancement of lead candidate, Remedisc, for degenerative disc disease --PARSIPPANY, N.J., April 20, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced a $3 million investment in Spine BioPharma in the form of a convertible note. USING EXPAREL® (BUPIVACAINE LIPOSOME INJECTABLE A cross functional panel discusses data, implementation of, and education considerations for EXPAREL. B. Wycke Baker, MD, MHA; Elizabeth Cherot, MBA, MD, FACOG PACIRA BIOSCIENCES LAUNCHES NATIONAL REGIONAL ANESTHESIA The initiative aims to educate clinicians on ultrasound-guided regional approaches to manage postsurgical pain. PARSIPPANY, N.J., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), a leading provider of innovative non-opioid pain management options, today announced a collaboration with Envision Physician Services to train anesthesiology clinicians on PACIRA BIOSCIENCES ANNOUNCES EQUITY INVESTMENT IN Supports Development of Promising Gene Therapy Platform for Osteoarthritis. PARSIPPANY, N.J., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the leading provider of innovative non-opioid pain management options, today announced that the company will lead an equity investment in GeneQuine Biotherapeutics GmbH. NEWS RELEASE FOR IMMEDIATE RELEASE NEWS RELEASE FOR IMMEDIATE RELEASE Pacira BioSciences Seeks Court Injunction to Protect Clinical Integrity of EXPAREL in the Face of Scientifically Flawed and Misleading Information Published in Anesthesiology Complaint challenges the American Society of Anesthesiologists for promoting biased, HOME | PACIRAABOUT USCOMMITMENTPRODUCTSPARTNERSHIPSNEWSEVENTS Overreliance on opioids in the postsurgical setting has set off a cascade of negative consequences, ranging from potentially severe adverse events to the risk of long-term use, misuse, and addiction.NEW PRODUCTS PAGE
Products EXPAREL® (bupivacaine liposome injectable suspension) is a local analgesic administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgicalpain.*
ABOUT US | PACIRA
Pacira is the leading provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving patient outcomes We’re working to meet the needs of health care practitioners and their patients Our in-depth knowledge of non-opioid pain management, coupled with our passion for delivering improved patient care, drives our commitment to providing solutionsPRODUCTS | PACIRA
EXPAREL® (bupivacaine liposome injectable suspension) is changing the way we treat postsurgical pain Low- or no-opioid pain control is possible with EXPAREL EXPAREL is a local anesthetic administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain.CAREERS | PACIRA
Pacira BioSciences, Inc. is an Equal Opportunity Employer.All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, or protected veteran status and willCONTACT PACIRA
Contact Us CONTACT PACIRA. × Science Center Campus. 10410 Science Center Drive San Diego, CA 92121 (858) 625 2424IOVERA | PACIRA
ioveraº allows health care providers to control pain by delivering precise, controlled doses of cold temperature to a targeted nerve The ioveraº technology represents a revolutionary cryotherapy platform The ioveraº system is a novel, FDA-approved non-opioid treatment that alleviates pain through a mechanism known as cryoanalgesia, which applies intensely focused cold therapy to a specific HIGHLIGHTS OF PRESCRIBING INFORMATION EXPAREL. • In patients undergoing bunionectomy, a total of 106 mg (8 mL) of EXPAREL was administered, with 7 mL infiltrated into the tissues surrounding the osteotomy, and 1 mL INVESTORS | PACIRA BIOSCIENCES, INC. Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of new pharmaceutical products, based on its proprietary DepoFoam® drug delivery technology, for use in hospitals and ambulatory surgerycenters.
PACIRA BIOSCIENCES LAUNCHES NATIONAL REGIONAL ANESTHESIA The initiative aims to educate clinicians on ultrasound-guided regional approaches to manage postsurgical pain. PARSIPPANY, N.J., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), a leading provider of innovative non-opioid pain management options, today announced a collaboration with Envision Physician Services to train anesthesiology clinicians on HOME | PACIRAABOUT USCOMMITMENTPRODUCTSPARTNERSHIPSNEWSEVENTS Overreliance on opioids in the postsurgical setting has set off a cascade of negative consequences, ranging from potentially severe adverse events to the risk of long-term use, misuse, and addiction.NEW PRODUCTS PAGE
Products EXPAREL® (bupivacaine liposome injectable suspension) is a local analgesic administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgicalpain.*
ABOUT US | PACIRA
Pacira is the leading provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving patient outcomes We’re working to meet the needs of health care practitioners and their patients Our in-depth knowledge of non-opioid pain management, coupled with our passion for delivering improved patient care, drives our commitment to providing solutionsPRODUCTS | PACIRA
EXPAREL® (bupivacaine liposome injectable suspension) is changing the way we treat postsurgical pain Low- or no-opioid pain control is possible with EXPAREL EXPAREL is a local anesthetic administered at the time of surgery to control pain and reduce or eliminate the use of opioids for acute postsurgical pain.CAREERS | PACIRA
Pacira BioSciences, Inc. is an Equal Opportunity Employer.All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, or protected veteran status and willCONTACT PACIRA
Contact Us CONTACT PACIRA. × Science Center Campus. 10410 Science Center Drive San Diego, CA 92121 (858) 625 2424IOVERA | PACIRA
ioveraº allows health care providers to control pain by delivering precise, controlled doses of cold temperature to a targeted nerve The ioveraº technology represents a revolutionary cryotherapy platform The ioveraº system is a novel, FDA-approved non-opioid treatment that alleviates pain through a mechanism known as cryoanalgesia, which applies intensely focused cold therapy to a specific HIGHLIGHTS OF PRESCRIBING INFORMATION EXPAREL. • In patients undergoing bunionectomy, a total of 106 mg (8 mL) of EXPAREL was administered, with 7 mL infiltrated into the tissues surrounding the osteotomy, and 1 mL INVESTORS | PACIRA BIOSCIENCES, INC. Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of new pharmaceutical products, based on its proprietary DepoFoam® drug delivery technology, for use in hospitals and ambulatory surgerycenters.
PACIRA BIOSCIENCES LAUNCHES NATIONAL REGIONAL ANESTHESIA The initiative aims to educate clinicians on ultrasound-guided regional approaches to manage postsurgical pain. PARSIPPANY, N.J., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), a leading provider of innovative non-opioid pain management options, today announced a collaboration with Envision Physician Services to train anesthesiology clinicians onCONTACT PACIRA
Contact Us CONTACT PACIRA. × Science Center Campus. 10410 Science Center Drive San Diego, CA 92121 (858) 625 2424 INNOVATION DASHBOARD Pacira Innovation Hub The Innovation Hub features on-demand education covering a broad spectrum of topics designed to stimulate conversation and spark novel thinking in health care. Use the filters below to find the materials you are looking for or explore our Pacira Podcasts. PACIRA LEGAL INFORMATION Pacira BioSciences, Inc. has prepared this information in good faith based on current information reasonably available. No liability whatsoever is accepted and no representation, warranty or undertaking, express or implied, is or will be made by Pacira or any of Pacira's affiliates, or any of their respective agents, directors, officers, employees, advisers, or representatives ("Agents"), forDEPOFOAM | PACIRA
The DepoFoam carrier matrix consists of microscopic, spherical, lipid-based particles composed of a honeycomb of numerous, non-concentric, internal aqueous chambers containing the encapsulateddrug.
PACIRA BIOSCIENCES ANNOUNCES INVESTMENT IN SPINE BIOPHARMA -- Supports clinical advancement of lead candidate, Remedisc, for degenerative disc disease --PARSIPPANY, N.J., April 20, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced a $3 million investment in Spine BioPharma in the form of a convertible note.PACIRA IN THE NEWS
The Investor Relations website contains information about Pacira BioSciences, Inc.'s business for stockholders, potential investors, and financial analysts. USING EXPAREL® (BUPIVACAINE LIPOSOME INJECTABLE A cross functional panel discusses data, implementation of, and education considerations for EXPAREL. B. Wycke Baker, MD, MHA; Elizabeth Cherot, MBA, MD, FACOG PACIRA BIOSCIENCES LAUNCHES NATIONAL REGIONAL ANESTHESIA The initiative aims to educate clinicians on ultrasound-guided regional approaches to manage postsurgical pain. PARSIPPANY, N.J., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), a leading provider of innovative non-opioid pain management options, today announced a collaboration with Envision Physician Services to train anesthesiology clinicians on PACIRA BIOSCIENCES ANNOUNCES EQUITY INVESTMENT IN Supports Development of Promising Gene Therapy Platform for Osteoarthritis. PARSIPPANY, N.J., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the leading provider of innovative non-opioid pain management options, today announced that the company will lead an equity investment in GeneQuine Biotherapeutics GmbH. NEWS RELEASE FOR IMMEDIATE RELEASE NEWS RELEASE FOR IMMEDIATE RELEASE Pacira BioSciences Seeks Court Injunction to Protect Clinical Integrity of EXPAREL in the Face of Scientifically Flawed and Misleading Information Published in Anesthesiology Complaint challenges the American Society of Anesthesiologists for promoting biased, Skip to main contentToggle navigation
MAIN NAVIGATION
* About Us
* About Us
* Board of Directors* Compliance
* Commitment
* Innovation Hub
* Products
* EXPAREL
* ioveraº
* DepoFoam
* Partnerships
* Partnerships for the Future * Grants and Corporate Giving* News
* In the News
* Archive
* Events
* Investors
* Overview
* SEC Filings
* Analyst Coverage
* Corporate Governance* Investor FAQs
* Careers
EXPAREL® NOW APPROVED IN PEDIATRICS FOR POSTSURGICAL PAIN MANAGEMENTLearn More
ASA Complaint
WE’RE DRIVING INNOVATION TO PROVIDE BETTER WAYS TO SAFELY AND EFFECTIVELY MANAGE PAIN ADVANCING PATIENT CARE Video Player is loading.Play VideoPlay
Mute
Current Time 0:00
/
Duration -:-
Loaded: 0%
Stream Type LIVESeek to live, currently playing liveLIVE Remaining Time -0:00Playback Rate
1x
Chapters
* Chapters
Descriptions
* descriptions off, selectedCaptions
* captions settings, opens captions settings dialog * captions off, selectedAudio Track
Fullscreen
This is a modal window. Beginning of dialog window. Escape will cancel and close the window. TextColorWhiteBlackRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentBackgroundColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentTransparentWindowColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyTransparentSemi-TransparentOpaque Font Size50%75%100%125%150%175%200%300%400%Text Edge StyleNoneRaisedDepressedUniformDropshadowFont FamilyProportional Sans-SerifMonospace Sans-SerifProportional SerifMonospace SerifCasualScriptSmall Caps Reset restore all settings to the default valuesDoneClose Modal Dialog End of dialog window. ADVANCING PATIENT CARE Overreliance on opioids in the postsurgical setting has set off a cascade of negative consequences, ranging from potentially severe adverse events to the risk of long-term use, misuse, and addiction. Why we push for change REDEFINING PAIN MANAGEMENT * EXPAREL® (bupivacaine liposome injectable suspension)* DepoFoam®
* iovera°
Our innovative, opioid-free alternativesDEPOFOAM®
EXPAREL combines bupivacaine with the DepoFoam® drug delivery platform to provide long-lasting postsurgical pain control when administered via infiltration, field block, or interscalene brachialplexus nerve block.
Learn More
Our long-acting local analgesic, EXPAREL® (bupivacaine liposome injectable suspension), is a non-opioid medication administered at the time of surgery to control pain while reducing opioid* requirements. *The clinical benefit of the decrease in opioid consumption was not demonstrated in the pivotal trials.Learn More
Our iovera° system is an FDA-approved handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targeted nerves, interrupting the nerve’s ability to transmit a pain signal. Results can be felt immediately after iovera° treatment with pain relief that can last three months, and in some cases longer, as the nerve regenerates over time. The iovera° system offers a non-opioid solution for the management of pain associated with both orthopedic surgery and persistent orthopedic conditions such as osteoarthritis.Learn More
THE PACIRA WEBSITE IS INTENDED FOR US RESIDENTS ONLY Are you a US Resident?Yes
No
* Contact Us
* Legal
* Site Map
* Privacy Notice
EXPAREL® (bupivacaine liposome injectable suspension), the EXPAREL logo, ioverao, the ioverao logo, Pacira, and the Pacira logo are licensed by or registered trademarks of Pacira Pharmaceuticals, Inc. All other trademarks referenced herein are the property of their respectiveowners.
©2021 Pacira BioSciences, Inc. | PP-EX-IO-US-0057 | 06/2020 This website uses cookies to give you a better browsing experience. By continuing to use this site you agree to our use of cookies. For additional information see our Cookie Notice .More info
OK, I agree No, thanksDetails
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0